scholarly journals Variation in intravenous iron use internationally and over time: the Dialysis Outcomes and Practice Patterns Study (DOPPS)

2013 ◽  
Vol 28 (10) ◽  
pp. 2570-2579 ◽  
Author(s):  
G. R. Bailie ◽  
M. Larkina ◽  
D. A. Goodkin ◽  
Y. Li ◽  
R. L. Pisoni ◽  
...  
Keyword(s):  
Practice Patterns ◽  
Intravenous Iron ◽  
Dialysis Outcomes ◽  
Over Time

scholarly journals Data from the Dialysis Outcomes and Practice Patterns Study validate an association between high intravenous iron doses and mortality

2015 ◽  
Vol 87 (1) ◽  
pp. 162-168 ◽  
Author(s):  
George R. Bailie ◽  
Maria Larkina ◽  
David A. Goodkin ◽  
Yun Li ◽  
Ronald L. Pisoni ◽  
...  
Keyword(s):  
Practice Patterns ◽  
Intravenous Iron ◽  
Dialysis Outcomes

scholarly journals The Dialysis Outcomes and Practice Patterns Study (DOPPS) Practice Monitor: Rationale and Methods for an Initiative to Monitor the New US Bundled Dialysis Payment System

2011 ◽  
Vol 57 (6) ◽  
pp. 822-831 ◽  
Author(s):  
Bruce Robinson ◽  
Douglas Fuller ◽  
Dawn Zinsser ◽  
Justin Albert ◽  
Brenda Gillespie ◽  
...  
Keyword(s):  
Practice Patterns ◽  
Payment System ◽  
Dialysis Outcomes

MO792CONTEMPORARY MINERAL AND BONE DISORDER MARKERS AND TREATMENT AMONG HEMODIALYSIS PATIENTS IN THE EUROPEAN DIALYSIS OUTCOMES AND PRACTICE PATTERNS STUDY (DOPPS)*

2021 ◽  
Vol 36 (Supplement_1) ◽  
Author(s):  
Brian Bieber ◽  
Indranil Dasgupta ◽  
Pieter Evenepoel ◽  
Stefan H Jacobson ◽  
Piergiorgio Messa ◽  
...  
Keyword(s):  
Vitamin D ◽  
Practice Patterns ◽  
Hemodialysis Patients ◽  
Serum Phosphorus ◽  
Active Vitamin ◽  
Mineral And Bone Disorder ◽  
Bone Disorder ◽  
Country Differences ◽  
Dialysis Outcomes ◽  
The Uk

Abstract Background and Aims Chronic kidney disease mineral and bone disorder (CKD-MBD) is characterized by abnormalities in serum calcium, phosphorus, and parathyroid hormone (PTH) and associated with morbidity and mortality. Previous publications from the Dialysis Outcomes and Practice Patterns Study (DOPPS) have demonstrated country differences in the prevalence and treatment of CKD-MBD among hemodialysis patients in participating European countries. We aim to compare the distribution of CKD-MBD related labs and treatments across countries in a contemporary population of European hemodialysis patients. Method DOPPS is an international prospective cohort study of hemodialysis patients ≥18 years of age. Patients are enrolled randomly from a representative sample of dialysis facilities within each nation at the start of each study phase. The current analysis includes n=1,701 patients from 91 facilities in the initial prevalent cross section of Europe DOPPS phase 7 (2019-present; Belgium, Germany, Italy, Spain, Sweden, UK). Results from Belgium should be considered preliminary as initial questionnaire completion is ongoing. Results The % of patients with a high PTH (>600 pg/mL) ranged from 6% in Italy to 24% in the UK, with 12-17% having high PTH in all other countries. Mean serum total calcium ranged from 8.7 in Germany to 9.1 mg/dL in the UK (Table). Mean serum phosphorus varied from 4.5 in Belgium to 5.3 mg/dL in Germany. Dialysate calcium of 2.5 mEq/L was predominant in Germany, Sweden, and the UK while 3.0 mEq/L was the most common prescription in Belgium, Italy, and Spain. Calcimimetic prescription ranged from 13% in the UK to 32% in Spain. Etelcalcetide prescription ranged from 1% in the UK to 12% in Spain and 14% in Italy. Active vitamin D prescription ranged from 27% in Belgium to 75% in Sweden. Nearly all vitamin D prescriptions were administered intravenously in Spain versus about half in Italy; in all other countries, the route of active vitamin D administration was primarily oral. Patient age and dialysis vintage varied by country, potentially contributing to some of the observed country differences in MBD marker levels and treatment practices. Conclusion CKD-MBD related abnormalities in PTH, serum phosphorus and calcium remain common in European dialysis patients, with prevalence varying considerably by country. Substantial international variation in CKD-MBD treatments was also observed in prescription of vitamin D and calcimimetics. Uptake of the relatively new calcimimetic, etelcalcetide, varied considerably by country. A detailed understanding of the effect of treatment variation on CKD-MBD marker levels and patient outcomes is needed to provide important insights for the European HD community in optimizing management of secondary hyperparathyroidism.

scholarly journals Hemodialysis vascular access preferences and outcomes in the Dialysis Outcomes and Practice Patterns Study (DOPPS)

2002 ◽  
Vol 61 (6) ◽  
pp. 2266-2271 ◽  
Author(s):  
Eric W. Young ◽  
Dawn M. Dykstra ◽  
David A. Goodkin ◽  
Donna L. Mapes ◽  
Robert A. Wolfe ◽  
...  
Keyword(s):  
Vascular Access ◽  
Practice Patterns ◽  
Hemodialysis Vascular Access ◽  
Dialysis Outcomes

scholarly journals Anemia and iron deficiency among chronic kidney disease Stages 3–5ND patients in the Chronic Kidney Disease Outcomes and Practice Patterns Study: often unmeasured, variably treated

2019 ◽  
Vol 13 (4) ◽  
pp. 613-624 ◽  
Author(s):  
Michelle M Y Wong ◽  
Charlotte Tu ◽  
Yun Li ◽  
Rachel L Perlman ◽  
Roberto Pecoits-Filho ◽  
...  
Keyword(s):  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Iron Deficiency ◽  
Management Practices ◽  
Practice Patterns ◽  
Intravenous Iron ◽  
Cross Sectional ◽  
Disease Outcomes ◽  
The Usa ◽  
Hemoglobin Measurement

Abstract Background International variation in anemia assessment and management practices in chronic kidney disease (CKD) is poorly understood. Methods We performed a cross-sectional analysis of anemia laboratory monitoring, prevalence and management in the prospective Chronic Kidney Disease Outcomes and Practice Patterns Study (CKDopps). A total of 6766 participants with CKD Stages 3a–5ND from nephrology clinics in Brazil, France, Germany and the USA were included. Results Among patients with anemia (hemoglobin <12 g/dL), 36–58% in Brazil, the USA and Germany had repeat hemoglobin measured and 40–61% had iron indices measured within 3 months of the index hemoglobin measurement. Anemia was more common in the USA and Brazil than in France and Germany across CKD stages. Higher ferritin and lower iron saturation (TSAT) levels were observed with lower hemoglobin levels, and higher ferritin with more advanced CKD. The proportion of anemic patients with ferritin <100 ng/mL or TSAT <20% ranged from 42% in Brazil to 53% in France and Germany, and of these patients, over 40% in Brazil, Germany and the USA, compared with 27% in France, were treated with oral or intravenous iron within 3 months after hemoglobin measurement. The proportion of patients with hemoglobin <10 g/dL treated with erythropoiesis-stimulating agents ranged from 28% in the USA to 57% in Germany. Conclusions Hemoglobin and iron stores are measured less frequently than per guidelines. Among all regions, there was a substantial proportion of anemic patients with iron deficiency who were not treated with iron, highlighting an area for practice improvement in CKD care.

scholarly journals Sex-Specific Differences in Hemodialysis Prevalence and Practices and the Male-to-Female Mortality Rate: The Dialysis Outcomes and Practice Patterns Study (DOPPS)

PLoS Medicine ◽  
2014 ◽  
Vol 11 (10) ◽  
pp. e1001750 ◽  
Author(s):  
Manfred Hecking ◽  
Brian A. Bieber ◽  
Jean Ethier ◽  
Alexandra Kautzky-Willer ◽  
Gere Sunder-Plassmann ◽  
...  
Keyword(s):  
Mortality Rate ◽  
Practice Patterns ◽  
Female Mortality ◽  
Dialysis Outcomes ◽  
Male To Female
Sign in / Sign up

Export Citation Format

Share Document